

## Clinical research article

**Full title:** Levels of high-sensitive troponin T and mid-regional pro-adrenomedullin after COVID-19 vaccination in vulnerable groups: a prospective study on subtle and persistent cardiovascular involvement

**Short running head:** Cardiovascular biomarkers after COVID-19 vaccines

**Authors:** Martin Möckel<sup>1</sup>, Samipa Pudasaini<sup>1</sup>, Ngoc Han Le<sup>2</sup>, Dörte Huscher<sup>3</sup>, Fabian Holert<sup>1</sup>, David Hillus<sup>2</sup>, Pinkus Tober-Lau<sup>2</sup>, Florian Kurth<sup>2</sup>, Leif Erik Sander<sup>2, 4</sup>

### **Affiliations:**

**1** Department of Emergency and Acute Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, 13353/10117 Berlin, Germany. **2** Department of Infectious Diseases and Pulmonary Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, 13353/10117 Berlin, Germany. **3** Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Campus Virchow-Klinikum and Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, 13353/10117 Berlin, Germany. **4** Berlin Institute of Health at Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany.

**Corresponding author:** Univ.-Prof. Dr. med. Martin Möckel, Charité – Universitätsmedizin Berlin (ORCID-ID: 0000-0002-7691-3709), Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Emergency and Acute Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charitéplatz 1, 13353/10117 Berlin, Tel.: +49(0)30-450-553203, E-Mail: [martin.moeckel@charite.de](mailto:martin.moeckel@charite.de).

**Word Count:** 6166 reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Abstract:**

2 **Background:** This study examines potential, subtle and persistent adverse effects of COVID-19  
3 vaccines on the cardiovascular system. Vaccine-associated myocardial injury was analysed by  
4 measuring high-sensitive troponin T (hsTnT); mid-regional pro-adrenomedullin (MR-proADM) levels  
5 were evaluated to assess endothelial dysfunction.

6 **Methods:** This was a prospective study with a vulnerable population of healthcare workers (HCWs)  
7 and elderly patients (> 70 years) who were vaccinated with either one dose of ChAdOx1 nCov-19  
8 adenoviral vector vaccine (AZ) followed by one dose of the BNT162b2 messenger RNA vaccine (BNT),  
9 or with two doses of BNT (12<sup>th</sup> of January - 30<sup>th</sup> of November 2021). HsTnT and MR-proADM were  
10 measured in blood samples at three visits (V<sub>1</sub>: 1<sup>st</sup> immediately before vaccination; V<sub>2, 3</sub>: 3-4 weeks  
11 after 1<sup>st</sup> and 2<sup>nd</sup> vaccination). HsTnT of HCWs was compared to a healthy reference population.

12 **Results:** N=162 volunteers were included (V<sub>1</sub>=161; V<sub>2, 3</sub>=162 each). N=74 (45.7%) received AZ/BNT  
13 and n=88 (54.3%) received BNT/BNT (elderly: n=20 (12.3%), HCWs: n=68 (42.0%)). Median hsTnT  
14 levels were 4ng/L, 5ng/L and 4ng/L (V<sub>1</sub>-V<sub>3</sub>) for AZ/BNT and at 5ng/L, 6ng/L and 6ng/L (V<sub>1</sub>-V<sub>3</sub>) for  
15 BNT/BNT. Compared to the reference population (n=300), hsTnT was significantly higher at all visits  
16 for both vaccination groups (p<0.01), without differences between the AZ/BNT and BNT/BNT cohort.  
17 MR-proADM values were 0.43nmol/L, 0.45nmol/L, 0.44nmol/L (V<sub>1</sub>-V<sub>3</sub>) in the AZ/BNT cohort and  
18 0.49nmol/L, 0.44nmol/L, 0.47nmol/L for BNT/BNT, respectively. Change of median hsTnT and MR-  
19 proADM between visits did not show significant increases. One HCW case had a permanent and  
20 three a transient hsTnT increase  $\geq 14$ ng/L.

21 **Conclusion:** With one individual exception, no overall subtle, persistent cardiovascular involvement  
22 was observed after the 2<sup>nd</sup> COVID-19 vaccination.

23

24 **Keywords:** COVID-19 vaccination; high-sensitive troponin T; persistent myocardial injury; mid-  
25 regional pro-adrenomedullin; endothelial dysfunction.

## 26 **Introduction:**

27           Coronavirus disease 2019 (COVID-19) vaccines are generally safe and effective in reducing  
28 the severity of SARS-CoV-2 infections and their complications (1, 2). About 70.6% of the world's  
29 population has received at least one vaccine dose, and over 13 billion doses have been given  
30 worldwide (3). To ensure the safety of COVID-19 vaccines, short- and long-term adverse events are  
31 continuously monitored by active and passive pharmacovigilance and post-marketing studies and  
32 vaccine safety is intensely studied (4, 5). The International Coalition of Medicines Regulatory  
33 Authorities, representing 38 regulatory agencies, recently issued a joint statement on reassuring  
34 safety data showing that COVID-19 vaccines have a very good safety profile in all age groups,  
35 including children and people with underlying medical conditions (6). Rare adverse events include  
36 complications of the cardiac system, like COVID-19 vaccine-associated myocarditis and pericarditis,  
37 as well as adverse effects on the vasculature, such as an impaired endothelial function as well as  
38 arterial and venous thrombosis (7-10).

### 39 COVID-19 vaccination and the cardiac system

40           Although rare, myo- and pericarditis are the most frequent adverse cardiac events following  
41 COVID-19 vaccinations (11, 12) and were first reported in April 2021 (12). Today, incidence of myo-  
42 and pericarditis is (region-specifically) estimated at 1 to 11 per 100,000 vaccinees (12, 13). Incidence  
43 is highest among young adult males, particularly following the second dose of Moderna (MOD) or  
44 BioNTech/Pfizer (BNT) messenger ribonucleic acid (mRNA) vaccine (12). In patients with mRNA-  
45 vaccine related myo- and/or pericarditis, cardiomyocyte necrosis was almost always detectable, as  
46 determined by measurements of the cardiac-specific biomarker high-sensitive troponin T (hsTnT) (14,  
47 15). For instance, in a study by Oster *et al.*, elevated hsTnT was observed in 97.9% (792/809) of  
48 COVID-19 vaccine-associated cases of myo- and/or pericarditis, as well as further major adverse  
49 cardiac events (14). Hence, hsTnT measurement is of high relevance for the diagnostic identification  
50 of patients with vaccine-related cardiac adverse events.

51           So far, cardiomyocyte injury in COVID-19 vaccine recipients was primarily analysed in study  
52   populations that presented with clinically manifest and acute cardiac symptoms (7). Yet, it has rarely  
53   been investigated if and to what extent a subtle, chronic post-vaccine myocardial involvement occurs  
54   in a vaccinated population even in the absence of typical symptoms. Mainly three studies actively  
55   monitored of hsTnT levels in a BNT-vaccinated cohort. Mansanguan *et al.* analysed 301 adolescents  
56   of whom four had signs of a subclinical myocarditis, one suffered a clinically manifest myopericarditis  
57   and two a pericarditis after the 2<sup>nd</sup> BNT162b2 vaccine. Here, cardiac biomarkers were measured at  
58   baseline, day 3, 7 and 14 (optionally) (16). Levi and colleagues observed vaccine-associated  
59   cardiomyocyte injury in two participants (0.6%), with one being symptomatic and one asymptomatic,  
60   2 to 4 days after having received their 4<sup>th</sup> BNT dose (17). Lastly, Buergerin *et al.* detected the highest  
61   rate of 2.8% (women: 20/777; men: 2/777) in their hospital employee cohort presenting with a  
62   vaccine-induced myocardial injury on day 3 after receipt of MOD mRNA booster (18). All three  
63   studies described cardiac involvement as mild and transient and mainly defined it as an acute hsTnT  
64   elevation above the 99<sup>th</sup> percentile of upper reference limit (URL) (16, 18, 19). Electrocardiograms  
65   and echocardiography were normal in the majority of affected participants (17, 18).

66           In order to further strengthen safety data and confidence in COVID-19 vaccines, additional  
67   research is warranted to assess possible subtle and subclinical myocardial damage after COVID-19  
68   vaccination, also with regards to varying vaccination regimens (vector versus mRNA or heterologous  
69   vaccination). Furthermore, as emphasised in a recent editorial by Levi *et al.*, longitudinal  
70   observations of hsTnT levels over time, e.g. including pre-vaccination status and follow-up samples  
71   after booster vaccination, would be of interest to evaluate if any occurring subclinical cardiac injury is  
72   likely self-limiting or becomes chronic (17).

### 73   COVID-19 vaccination and the vascular system

74           Mainly one study has investigated possible acute effects of COVID-19 vaccines on the  
75   vascular system (20). The authors observed a short-term deterioration of endothelial function in the

76 first 24 hours after the 2<sup>nd</sup> BN vaccine dose. The extent of endothelial involvement was described as  
77 far lower than in COVID-19, which in turn has been linked to endothelial cell infection and  
78 endotheliitis (20). In COVID-19 patients, the biomarker mid-regional pro-adrenomedullin (MR-  
79 proADM), an endothelium-related peptide with vasodilatory properties, was used to evaluate the  
80 severity of endothelial dysfunction (21). Measurements of MR-proADM levels to assess possible  
81 short- and long-term endothelial injury in COVID-19 vaccine recipients have not been analysed so far.

## 82 Study focus

83 By conducting a prospective observational study, we investigated subacute, subtle, and  
84 subclinical cardiomyocyte injury in two risk populations with follow-ups until 4 weeks (optionally  
85 longer) after completion of the original COVID-19 basic vaccination regimen. We hypothesize that  
86 hsTnT levels remain unchanged during follow-up, indicating no significant rise in myocardial injury in  
87 the short- and long-term compared to baseline. Secondly, we sought to analyse endothelial function  
88 based on levels of MR-proADM throughout the study period. With these two approaches, we aimed  
89 to address current knowledge gaps concerning chronic cardiovascular effects of COVID-19  
90 vaccination.

## 91 **Methods:**

### 92 Study design and study population:

93 The participants were recruited within the multicentre prospective observational studies,  
94 EICOV, COVIMMUNIZE and COVIM and consisted of health care workers (HCWs) of Charité –  
95 Universitätsmedizin Berlin as well as elderly/senior patients (> 70 years) at a general practitioner’s  
96 office in Berlin, Germany; two different types of risk populations in the pandemic. While vulnerability  
97 of HCWs is caused by their regular exposition to infectious patients, elderly mainly fall into this  
98 category due to their compromised immune response and multi-morbidity (22, 23). All participants  
99 received their first two COVID-19 vaccinations between 12<sup>th</sup> of January and 22<sup>nd</sup> of June 2021 with  
100 either a combination of AZ (AstraZeneca)/BNT (only for HCWs) or BNT/BNT (HCWs or elderly).

101 Booster vaccinations (3<sup>rd</sup> and 4<sup>th</sup>) were only mRNA-based (BNT or MOD). Key inclusion criteria were  
102 the ability to give written informed consent by the participants or via their legal representative, no  
103 contraindications to receiving a COVID-19 vaccination and an age of  $\geq 18$  years at the time of  
104 enrolment.

105 Three main visit timepoints (V<sub>1</sub>-V<sub>3</sub>) were conducted. V<sub>1</sub>: at baseline, i.e., 7 to 0 days before the 1<sup>st</sup>  
106 vaccination; V<sub>2</sub>: 3-4 weeks after the 1<sup>st</sup> vaccination and V<sub>3</sub>: 3-4 weeks after the 2<sup>nd</sup> vaccination (Figure  
107 (Fig.) 1). Prior work on this topic has shown that cardiovascular biomarkers, if elevated in the acute  
108 setting, usually rise and fall within 1-2 weeks after vaccinations. By choosing an interval of 3-4 weeks  
109 post-vaccination for biomarker measurement, we aimed to assess subacute or persistent hsTnT  
110 elevation (16). Participants that opted to participate in the follow-up study COVIM-Boost, a 4<sup>th</sup> visit  
111 (V<sub>4</sub>) and 5<sup>th</sup> visit (V<sub>5</sub>) was captured and is reported here for HCWs as part of an ancillary analysis up to  
112 50 days after the 3<sup>rd</sup> and 4<sup>th</sup> vaccination (with either BNT or MOD), respectively (Supplementary Fig.  
113 1). At all visits, serum and ethylenediaminetetraacetic acid (EDTA) blood samples were collected. MR-  
114 proADM was measured in EDTA plasma [nmol/L] on the Kryptor Compact Plus device (Thermo Fisher  
115 Scientific, Waltham, MA, USA). The clinically relevant cut-off was set at  $\geq 0.75$  nmol/L (24).  
116 Depending on the sample availability, EDTA or serum samples were used for measuring hsTnT (via  
117 Cobas e801, Roche Diagnostics, Mannheim, Germany). In the diagnostic exclusion procedure of a  
118 myocardial infarction, relevant hsTnT levels are defined as being  $>$  the 99<sup>th</sup> percentile of URL (25).  
119 This definition was also adopted by prior studies with a research question similar to ours (16-18).  
120 However, in a study by Barbier *et al.* the authors pointed out that new, subclinical cardiomyocyte  
121 injury, detected in late enhancement magnetic resonance imaging, may only be reflected in minor  
122 troponin elevations (of 4.1ng/L to 5.9ng/L) and slight increases also correlate with a negative  
123 prognosis (26). Additionally, in cases of SARS-CoV-2 infections with cardiac involvement,  
124 troponinemia was likewise mostly mild (27). Therefore, to also capture a possibly subtle but relevant  
125 troponin increase, we focused on all changes in hsTnT levels in the course of the visits and put it in  
126 relation to the initial baseline hsTnT value of the respective participant. Cases with a hsTnT elevation

127 > the 99<sup>th</sup> percentile cut-off value were presented and interpreted separately. HsTnT levels below the  
128 limit of detection (3ng/L), were set to 2.9ng/L for analyses.

129 Demographic and clinical characteristics of all participants, including age and sex,  
130 comorbidities and pre-medication were collected at enrolment and used for comparison with the  
131 reference cohort.

### 132 Reference population:

133 As a reference population, participants of the BIC-1 (**B**iomarkers in **C**ardiology **1**) study were  
134 used. This included HCWs of Charité – Universitätsmedizin Berlin that were recruited between 6<sup>th</sup> of  
135 July 2007 and 5<sup>th</sup> November 2007. Clinical exclusion criteria were the presence of a heart failure,  
136 other heart diseases, kidney or metabolic diseases and the intake of permanent medication.  
137 Therefore, this cohort was defined as a presumably healthy reference and was used for comparison  
138 of hsTnT values with our HCWs in the vaccination groups. Further inclusion criteria include a full  
139 employment contract, age of 18 years or older and no direct dependence on the study leader were  
140 required for inclusion. In this cohort, one visit ( $V_{R-1}$ ) was performed. HsTnT was measured in lithium-  
141 heparin blood samples on the same analyser module as in our vaccination cohorts (Cobas e801,  
142 Roche Diagnostics, Mannheim, Germany).

### 143 Hypothesis:

144 The primary hypothesis was that the distribution of hsTnT remains unchanged across all  
145 vaccination groups at the visits  $V_1$  to  $V_3$ . Therefore, we assumed that neither the combination of  
146 AZ/BNT, nor the BNT/BNT scheme would lead to a significant elevation of hsTnT compared to  
147 baseline levels at enrolment visit  $V_1$ . Secondly, we expected no relevant chronic endothelial  
148 dysfunction to be detected in the sense of a significant median difference between  $V_1$  to  $V_3$  of  
149 MRpro-ADM values in the observed time span.

150

151 Statistical analysis:

152 A basic description of the vaccination and reference groups was performed, including characteristics  
153 of sex, age, Body-Mass-Index (BMI), smoking status, comorbidities, and pre-medication at enrolment.  
154 If not indicated otherwise, metric values are presented as median with the associated interquartile  
155 range (IQR). Due to the skewed distribution of hsTnT and MR-proADM values, non-parametric tests  
156 were performed. The Mann-Whitney U test was applied to test the difference of hsTnT and MR-  
157 proADM levels between the vaccination groups, and the Wilcoxon signed rank test to investigate  
158 individual change between the visits for both biomarkers (differences  $V_2-V_1$ ,  $V_3-V_1$ ,  $V_3-V_2$ ). Correlation  
159 analyses were performed separately for sex between hsTnT and MR-proADM at each visit, and for  
160 both hsTnT and MR-proADM with age at  $V_1$ . Spearman's correlation coefficients were reported.  
161 Comparisons of hsTnT values between the reference group and the two vaccination cohorts (solely  
162 HCWs included here) were performed with the Kruskal-Wallis-test and pairwise post-hoc tests with  
163 Bonferroni correction. Mixed-effects models were calculated to examine effects of age (per 10  
164 years), sex, and the type of COVID-19 vaccination on the course of hsTnT and MR-proADM values,  
165 with random effects for the intercept. Since most visits were performed within a very close time  
166 window, the course of hsTnT and MR-proADM values were further explored in mixed-effects  
167 regression models treating the visits as repeated measurements, again including random effects for  
168 the intercept. In addition, mixed-effects regression models for propensity score-matched groups  
169 were calculated to examine effects of the vaccinations while controlling for potential confounders.

170 All analyses were performed using IBM SPSS Version 29 (IBM Corporation, Armonk, NY, USA)  
171 and R version 4.3.1 (2023-06-16 ucrt). A p-value  $<0.05$  was considered significant; for pairwise  
172 subgroup comparisons or parallel tests in visits  $V_1$  to  $V_3$ , p-values were adjusted for multiple testing.

173 Ethical approval and study registration:

174 The COVIM study (EA4/245/20), its preceding studies EICOV (EA4/245/20) and  
175 COVIMMUNIZE (EA4/244/20), the follow-up study COVIM-Boost (EA4/261/21) and the BIC-1 study



176 (EA2/030/07) were approved by the ethics committee of Charité – Universitätsmedizin Berlin. BIC-1  
177 was registered in the German register for clinical studies (DRKS-ID DRKS00000310) and COVIM in the  
178 European clinical trial register (EudraCT-2021–001512–28).

## 179 **Results:**

### 180 Characteristics of the study population:

181 Information on basic characteristics is provided in Table (Tab.) 1. In total, the study  
182 population consisted of 162 people in the vaccination group, including 142 (87.7%) HCWs and 20  
183 (12.3%) elderly patients (solely in the BNT/BNT group). Except for one person who missed the 1<sup>st</sup>  
184 visit, all participants were seen (at least) three times. Altogether, 74 (45.7%) participants received the  
185 combination of AZ/BNT, while 88 (54.3%) participants were vaccinated according to regular BNT/BNT  
186 regimen. In the AZ/BNT group, 41 (55.4%) participants and in the BNT/BNT population 49 (55.7%)  
187 were female, respectively. The median age was 33.2 years in the AZ/BNT and 37.6 years in the  
188 BNT/BNT group. Median BMI was 23.9 kg/m<sup>2</sup> and 23.8 kg/m<sup>2</sup>, respectively. Out of 148 available  
189 answers, 16 reported being either former current smokers.

### 190 [Position of Figure 1]

191 With regards to pre-medication, 9 (5.6%, 7/9 from the BNT/BNT cohort) reported receiving  
192 immunosuppressive therapy and 4 (2.5%, 3/4 from the BNT/BNT group) participants reported taking  
193 corticosteroids at enrolment. Furthermore, 14 (8.6%) participants reported taking antihypertensive  
194 drugs, 3 (1.9%) anticoagulants and 4 (2.5%) antiplatelet drugs as a permanent medication, the  
195 majority of participants on this medication belonging to the elderly group (see Tab. 1.)

196 Four (5.4%) participants in the AZ/BNT cohort, and 17 (19.3%) participants in the BNT/BNT  
197 cohort reported a cardiovascular disease at baseline, with hypertension (AZ/BNT: 4/74 (5.4%);  
198 BNT/BNT: 16/88 (18.2%)) as the most frequent condition. Chronic lung diseases were present in 10  
199 (6.2%) participants, with 4 (5.4%) being in the AZ/BNT and 6 (6.8%) participants in the BNT/BNT  
200 cohort. Other comorbidities, with 7 cases each (4.3%), included kidney disease (6/7 BNT/BNT),

201 rheumatologic/immunological diseases (4/7 BNT/BNT), and cancer (5/7 BNT/BNT). Diabetes,  
202 dementia, cerebrovascular or chronic haematological diseases were present in 5 (3.0%) cases, or less.

### 203 Characteristics of the reference population

204 The reference population included 300 individuals with a 1:1 female to male ratio. The  
205 median age was 39.0 years. For all 300 participants, hsTnT values were available at  $V_{R-1}$  for analysis.  
206 Comorbidities and pre-medication are not reported for this cohort since both were exclusion criteria  
207 (Tab. 1).

208 [Position of Table 1]

### 209 HsTnT measurement:

210 The median values of hsTnT in the AZ/BNT group were 4ng/L (IQR 4-6), 5ng/L (IQR 4-6) and  
211 4ng/L (IQR 4-6) for  $V_1$ ,  $V_2$ ,  $V_3$ , and for the BNT/BNT cohort 5ng/L (IQR 4-8), 6ng/L (IQR 4-9) and 6ng/L  
212 (4-8.5), respectively. Separated by HCWs and elderly (BNT/BNT), the seniors showed higher median  
213 values of 18ng/L (IQR 11-29), 15ng/L (IQR 10.5-25.5) and 13.5ng/L (IQR 10-22.5) during follow-up  
214 visits. HsTnT levels at  $V_1$ - $V_3$  in the AZ/BNT group were lower compared to the BNT/BNT cohort, at all  
215 visits, including at baseline ( $p_{V_1}=0.048$ ,  $p_{V_2}=0.003$ ,  $p_{V_3}<0.001$ ). The individual progression for  $V_1$ - $V_3$  is  
216 visualised in Fig. 2A, separated by vaccination regimen and sex. Median hsTnT in the reference  
217 population was 3.6ng/L (IQR 3.0-4.9, Fig. 3). For all HCWs, median hsTnT values were higher in males  
218 at all visits, including baseline ( $V_1$ :  $p=0.010$ ;  $V_2$ :  $p=0.003$ ;  $V_3$ :  $p=0.006$ ). Changes of median hsTnT  
219 values were 0ng/L (IQR -1.0 to 1.0;  $V_2$ - $V_1$ ), 0ng/L (IQR -1.0 to 0.0;  $V_3$ - $V_2$ ) and 0ng/L (IQR -1.0 to 0.0;  $V_3$ -  
220  $V_1$ ) in the AZ/BNT cohort (Fig. 2B). In the BNT/BNT population, changes were 0ng/L (IQR 0.0 to 1.0;  
221  $V_2$ - $V_1$ ), 0ng/L (IQR -1.0 to 1.0;  $V_3$ - $V_2$ ) and 0ng/L (IQR -1.0 to 1.0;  $V_3$ - $V_1$ ). There were no individual  
222 differences of hsTnT levels between all visits (AZ/BNT:  $V_2$ - $V_1$   $p=1.0$ ;  $V_3$ - $V_2$   $p=0.25$ ;  $V_3$ - $V_1$   $p=0.42$ ;  
223 BNT/BNT:  $V_2$ - $V_1$   $p=0.24$ ;  $V_3$ - $V_2$   $p=0.25$ ;  $V_3$ - $V_1$   $p=1.0$ ). Median changes of hsTnT for HCWs and elderly of  
224 the BNT/BNT cohort separately showed significant differences between  $V_2$  and  $V_1$  for HCWs (median

225 0 ng/L (IQR 0.0 to 1.0),  $p=0.029$ ) and between  $V_3$  and the two prior visits for elderly ( $V_3-V_2$ : median -1  
226 ng/L (IQR -4.0 to 0.0),  $p=0.038$ ;  $V_3-V_1$ : median -2ng/L (IQR -4.0 to 0.0),  $p=0.008$ ) were visible (Fig. 2C).

227 Four HCW cases stand out regarding their individual hsTnT levels and are therefore be  
228 reported separately in detail (Fig. 2A). One BNT/BNT participant (“w”, male, in his 30s, HCW) showed  
229 a steady hsTnT rise with values of 15ng/L, 21ng/L and 25ng/L ( $V_1-V_3$ ). At enrolment, he reported  
230 having had muscle pain and fever in the 7 days prior. At a follow-up visit 6 months after  $V_1$ , he stated  
231 having suffered from headache in the 7 days before presenting. Generally, no pre-existing medical  
232 conditions were reported by this participant. A second participant “x” (male, in his 20s, HCW,  
233 BNT/BNT), had a noticeable but transient hsTnT elevation at  $V_2$  and normalised again at  $V_3$  (7ng/L,  
234 17ng/L, 5ng/L). He reported the following baseline conditions: hypertensive heart disease, ulcus  
235 duodeni and vascular encephalopathy. Secondly, in the AZ/BNT population, two participants  
236 presented with a transient hsTnT elevation (participant “y” (male, in his 20s): 8ng/L, 14ng/L, 5ng/L;  
237 participant “z” (male, in his 20s): 6ng/L, 17ng/L, 6ng/L). Both did not report any symptoms, pre-  
238 medication or comorbidities.

239 In total, 16 study participants had at least one absolute hsTnT value > the 99<sup>th</sup> percentile of  
240 URL. Out of these, four participants presented with a normal baseline hsTnT value, while the other 12  
241 participants showed levels of  $\geq 14$ ng/L already at enrolment, prior to COVID-19 vaccination (Fig. 2A).

242 [Position of Figure 2]

243 Comparison of hsTnT levels in HCWs in the study cohort to HCWs in the reference cohort:

244 HsTnT levels in the reference cohort were significantly lower than in the AZ/BNT and  
245 BNT/BNT group at all three time points (at  $V_1$  and  $V_2$  compared to both vaccination groups:  $p<0.001$ ;  
246 at  $V_3$ : for  $V_{R-1}$ -AZ/BNT:  $p<0.001$  and for  $V_{R-1}$ -BNT/BNT:  $p=0.006$ ) (Fig. 3).

247 [Position of Figure 3]

248

249 MR-proADM measurement:

250 The MR-proADM median value was 0.43nmol/L (IQR 0.39-0.47), 0.45nmol/L (IQR 0.39-0.50)  
251 and 0.44nmol/L (IQR 0.38-0.52) ( $V_1$ - $V_3$ ) in the AZ/BNT population. In the BNT/BNT group, median MR-  
252 proADM levels were 0.49nmol/L (IQR 0.42-0.63), 0.44nmol/L (IQR 0.40-0.55) and 0.47nmol/L (IQR  
253 0.41-0.64), respectively (Fig. 4A). The comparison of MR-proADM between the vaccination groups  
254 revealed a significant difference at  $V_1$  and  $V_3$  ( $V_1$ :  $p<0.001$ ;  $V_2$ :  $p=0.336$ ;  $V_3$ :  $p=0.032$ ). Generally, 17  
255 participants (AZ/BNT:  $n=2$ ; BNT/BNT:  $n=15$ ) had at least one MR-pro ADM value  $> 0.75$ nmol/L.  
256 Median changes of MR-proADM levels between the visits  $V_1$  and  $V_2$  were 0.01nmol/L (IQR -0.02 to  
257 0.06; AZ/BNT) and -0.02nmol/L (IQR -0.05 to 0.02; BNT/BNT), with a small but significant difference  
258 between the vaccination groups ( $p=0.014$ ). Between  $V_2$  and  $V_3$  median values differed at -0.02nmol/L  
259 (IQR -0.05 to 0.04; AZ/BNT) and 0.01nmol/L (IQR -0.06 to 0.06; BNT/BNT) and median changes  
260 between the study visits  $V_1$  and  $V_3$  were 0.01nmol/L (IQR -0.03 to 0.06; AZ/BNT) and 0.00nmol/L (IQR  
261 -0.05 to 0.04; BNT/BNT), without statistical significance (Fig. 4B, C). One participant presented with a  
262 striking rise in MR-proADM levels during the study course (BNT/BNT group, in his 80s, male;  $V_1$ :  
263 1.1nmol/L,  $V_2$ : 1.1nmol/L,  $V_3$ : 1.5nmol/L) (Fig. 4A). He reported one cardiovascular comorbidity  
264 (hypertension) as well as an active cancer disease (Hodgkin lymphoma).

265 [Position of Figure 4]

266 Correlation models:

267 Correlation between hsTnT and MR-proADM values was assessed for all three visiting times  
268 (Suppl. Fig. 4A). The Spearman's correlation coefficient was low in both males ( $V_1$ :  $r=0.36$ ;  $V_2$ :  $r=0.08$ ;  
269  $V_3$ :  $r=0.38$ ) and females ( $V_1$ :  $r=0.55$ ;  $V_2$ :  $r=0.32$ ;  $V_3$ :  $r=0.57$ ), with a tendency to even lower  
270 correlation at  $V_2$ . A stronger correlation was seen between hsTnT levels and age (female:  $r=0.69$ ;  
271 male:  $r=0.45$ ) as well as MR-proADM and age (female:  $r=0.67$ ; male:  $r=0.56$ ) in female participants  
272 (Suppl. Fig. 4B and C).

273

274 Mixed-effects models:

275 Mixed-effect models were calculated for HCWs to identify factors that are associated with  
276 MR-proADM and hsTnT values over time, with the first vaccination as the anchor defining time 0 (Fig.  
277 2A, 4A). Sex, age (per 10 years), and the type of COVID-19 vaccine were used as independent  
278 variables. Results showed a significant effect of male sex and increasing age, but not the type of  
279 vaccine on both hsTnT and MRproADM levels. There was no linear effect over time, but when  
280 ignoring shifts in time of lab measurements relative to the first vaccination and treating the visits as  
281 repeated measurements, only  $V_2$  showed a significant increase compared to  $V_1$  with 0.41 ng/L (95%CI  
282 0.12 to 0.70,  $p=0.005$ ); no difference between  $V_3$  and  $V_1$  ( $\beta=0.13$  ng/L, 95%CI -0.15 to 0.42,  $p=0.356$ )  
283 was detected. When considering interaction, there was no interaction between this time effect and  
284 the type of vaccination, with the general time effect disappearing. For MRproADM, no significant  
285 effects except for age were seen (Tab. 2). In addition, mixed-effects regression models for propensity  
286 score-matched groups were utilised. 69 pairs were found per vaccination group and matched. Also  
287 here, no significant differences between the vaccination schemes were seen for both biomarkers.  
288 Results on this are presented in Supplementary Tab. 1.

289 [Position of Table 2]

290 Ancillary analysis:

291 In our follow-up study COVIM-Boost, a part of the participants of the original study were  
292 visited after booster vaccination (i.e. 3<sup>rd</sup> and 4<sup>th</sup> vaccination). Visits  $V_4$  and  $V_5$  are reported, if  
293 performed between 3-4 weeks after the vaccination and up to a maximum of 50 days afterwards.  
294 Altogether in HCWs, 25 3<sup>rd</sup> vaccinations and visits at  $V_4$  were registered while the 4<sup>th</sup> vaccination was  
295 applied to 12 people in total with 9 registered  $V_5$  visits. Details are listed in Supplementary Fig. 1.  
296 HsTnT median levels were 4 ng/L ( $V_4$ ) and 3 ng/L ( $V_5$ ), while median MR-proADM values were 0.46  
297 nmol/L ( $V_4$ ) and 0.54 nmol/L ( $V_5$ ). The hsTnT and MR-proADM progression for all visits  $V_1$  to  $V_5$  are  
298 visualised in Supplementary Fig. 2A and 3. Furthermore, we performed a post SARS-CoV-2

299 breakthrough infection measurement of hsTnT and MR-proADM up to 50 days after the infection.  
300 Participants with a reported breakthrough infection during the study course are marked in orange  
301 (Supplementary Fig. 2B).

## 302 **Discussion**

303 In this prospective observational study, we assessed if subtle, subacute and persistent  
304 myocardial involvement is detectable in a vulnerable population of HCWs and elderly patients  
305 following basic vaccination against COVID-19 with either an AZ/BNT or a BNT/BNT vaccination  
306 regimen. With the approach of an active surveillance, the biomarkers hsTnT and MR-proADM were  
307 measured at enrolment and at 3-4 weeks after the 1<sup>st</sup> and the 2<sup>nd</sup> vaccination, respectively.

### 308 *HsTnT levels after COVID-19 vaccination*

309 Regarding baseline hsTnT values ( $V_1$ ), the HCW vaccination cohort had a median hsTnT level  
310 of 4-5ng/L (IQR 4-6), whilst the reference population presented with a slightly lower median of  
311 3.6ng/L (IQR 3.0-4.9). As visible in our post-hoc pairwise comparisons, this difference in hsTnT at  $V_1$   
312 was significant. As  $V_1$  was performed before or right at the time of the 1<sup>st</sup> vaccination, this difference  
313 in baseline hsTnT values must be viewed as an indicator of pre-existing differences in patient  
314 characteristics. For instance, this observation may be explainable by the fact that the reference  
315 cohort did not include any participants with cardiological, nephrological or endocrinological diseases  
316 and were, therefore, presumably healthy, whilst in our study cohort, pre-existing diseases were not  
317 an exclusion criterion. Therefore, our results underline that the HCW cohort, if not preselected  
318 otherwise, represent a cohort that is working in health care, is <65 years of age, but that is otherwise  
319 not free of pre-existing illnesses. Furthermore, hsTnT values in our BNT/BNT senior group were  
320 comparatively high with a median of 18ng/L (IQR 11-29), with 10 out of 20 elderly participants  
321 already having an elevated hsTnT level above the 99<sup>th</sup> percentile of URL at baseline  $V_1$ . This is in  
322 accordance with common literature, indicating that increasing age accounts for higher troponin  
323 levels (28, 29), either as an independently increasing variable and/or as a sign for an underlying

324 (silent) disease, and this was also reproduced in our correlation analysis. For instance, Orlev and  
325 colleagues reported a median hsTnT at 14ng/L in nursing home patients at an age of >70 years even  
326 though the study population was described as asymptomatic (28). Self-evidentially, when discussing  
327 slight troponin differences, analytical imprecision of hsTnT measurement, especially in values below  
328 the 99<sup>th</sup> percentile of URL, must also be considered, besides the mentioned biological variability (30,  
329 31).

330 With regards to hsTnT time kinetics, median hsTnT values of all participants remained almost  
331 stable at 5ng/L for V<sub>1</sub>, V<sub>2</sub> and V<sub>3</sub>. When specifically analysing the vaccination cohorts stratified by  
332 vaccine type and age, BNT/BNT elderly and BNT/BNT HCWs, changes of median hsTnT over time  
333 were partially statistically significant, however, median absolute differences were still at 0ng/L for  
334 HCWs, indicating that these changes are not of clinical relevance. For the elderly, absolute changes  
335 were -1 ng/L and -2 ng/L, when comparing visit 3 to the prior visits, indicating, if anything, rather a  
336 slight post-vaccination decrease. In the group of medical personnel, four male participants stood out  
337 with a pronounced troponin elevation. All of them were young to mid-aged males, fitting to the  
338 typical group of vaccine recipients with rare vaccine-related myo- and/or pericarditis (12). Participant  
339 “w” who showed a transient hsTnT rise to 17ng/L at V<sub>2</sub>, did not report any corresponding symptoms.  
340 He had a prior known hypertensive heart disease. Here, the troponin elevation could be interpreted  
341 as a typical transient, subclinical myocarditis but without chronic residuals. Participant “x” presented  
342 with a steady increase in hsTnT levels up to 25ng/L at V<sub>3</sub>. However, no cardiovascular comorbidity  
343 was stated by him before enrolment. Therefore, the increase in hsTnT may either be a result of a yet  
344 unknown underlying cardiac disease and/or it may be interpreted as a subtle post-vaccine myocardial  
345 injury. The same hypothesis is assumed for persons “y” and “z”. In all cases, the hsTnT elevation was  
346 already detected after the 1<sup>st</sup> BNT vaccination (V<sub>2</sub>) and hsTnT elevation was transient in all cases  
347 except for one. Those with a transient hsTnT rise, returned to baseline levels or lower. The similar  
348 incidence of cardiac injury biomarker elevation following mRNA- and vector vaccines, is not in  
349 agreement with prior studies showing cardiomyocyte injury primarily after mRNA vaccination (12).

350 Also, our findings partly deviate from the literature, which reported rare cardiomyocyte damage in  
351 the context of myocarditis and/or pericarditis, mainly after the 2<sup>nd</sup> vaccine dose (12). When taking a  
352 look at the individual median troponin values of the BNT/BNT vaccinated elderly, it is noticeable that  
353 all 10 seniors with high absolute hsTnT levels in the course of the study period (V<sub>2</sub>, V<sub>3</sub>), already  
354 showed a relevant troponin elevation of  $\geq 14\text{ng/L}$  at the enrolment visit. Apart from this, no relevant  
355 vaccine-induced additional hsTnT elevation was detectable until V<sub>3</sub> amongst the elderly cohort.  
356 Therefore, our results support the notion that no overall subtle, subacute cardiomyocyte injury can  
357 be observed in this prospective cohort in temporal relation to the performed COVID-19 vaccinations.  
358 This appears to be the case irrespective of vaccination regimen, as indicated by our pairwise  
359 comparisons that showed no significant differences of hsTnT levels between the AZ/BNT and  
360 BNT/BNT groups (HCW sub-group) at V<sub>1</sub> to V<sub>3</sub>.

361 Existing studies on hsTnT and myocardial injury were so far performed either on HCWs or  
362 adolescents (16-18). Thus, mainly previous studies are comparable to the hsTnT results of our HCW  
363 sub-cohort, since the baseline characteristics of our elderly group differ strongly. Mansanguan and  
364 colleagues reported a relevant cardiac biomarker elevation in 7/301 (2.3%) cases, including 5 (1.6%)  
365 with cardiac troponin T  $\geq 14\text{ng/L}$  out of which 4 (1.3%) were described as occurrences of subclinical  
366 myocarditis with initially normal hsTnT levels, followed by a post-vaccine elevation that peaked at  
367 day 7 (16). These participants were between 13 to 17 years old; an age range that was not covered in  
368 our work, but according to the literature, includes most of the post-COVID-19-vaccine-associated  
369 myocarditis cases (12). However, for those 4 adolescents with subclinical troponin elevations, the  
370 researchers did not provide follow-up measurements at day 14 (16). Therefore, it is not possible to  
371 evaluate whether troponin elevations persisted or declined with time. In general, study objective,  
372 participant age and observation span differed largely from our work, making a direct comparison  
373 difficult. Regarding participant characteristics, our cohort is most similar to the one studied by Levi *et*  
374 *al.* who recruited 324 HCWs of whom 22 showed a hsTnT above the sex-specific 99<sup>th</sup> percentile at  
375 baseline and 27 showed elevated hsTnT within 2-4 days post-vaccination (4<sup>th</sup> BNT162b booster) (17).



376 However, the authors primarily focused on 2 participants who additionally showed a hsTnT rise of >  
377 50% compared to enrolment measurements and interpreted this as vaccine-related myocardial  
378 injury; both did not have a clinical myocarditis (17). A detailed characterization of the remaining  
379 HCWs with slightly elevated hsTnT would have also been of interest but was not provided in the  
380 publication. In contrast, we focused not only on hsTnT elevations above the URL and exceeding the  
381 reference change value, since slight elevations below the 99<sup>th</sup> percentile can, in the long term, also  
382 impact clinical outcomes (26). Our results differ from those of Buergin *et al.* who reported a mild and  
383 transient cardiomyocyte injury in a significantly higher proportion of participants in their cohort of  
384 hospital employees (2.8%; 22/777) 3 days after mRNA-1273 booster vaccination, with mainly female  
385 HCWs (2,57%; 20/777) being affected (18). This difference in sex distribution was not reproducible in  
386 our study. As described above, individual cases of a noticeable troponin rise were solely observed in  
387 male participants and, overall, median hsTnT levels, separated by sex, were significantly higher for  
388 our male population at all main visiting points. Also, the comparatively high cases of troponin  
389 elevation deviate from our results. However, here, it must be kept in mind that our first post-  
390 vaccination visit (V<sub>2</sub>) was performed up to 4 weeks after vaccination, with the aim of capturing  
391 persistent myocardial involvement. Therefore, our data does not allow for conclusions on possible  
392 acute troponin changes that may have occurred within the first days after vaccination. Yet, since  
393 other studies by Mansanguan *et al.* and Levi *et al.* did not find much lower incidences of myocardial  
394 injury in the immediate post-vaccine period (16, 17), possible other reasons for the deviating results  
395 of Buergin *et al.* must be considered. On the one hand, the authors chose the respective sex-specific  
396 URL, which was for females at 8.9ng/L and, therefore, clearly lower than 14ng/L (18). On the other  
397 hand, the distribution of sex was unbalanced in their study with an approximately 1:2 ratio of  
398 males:females (18). This difference in selection may have consequently resulted in higher numbers of  
399 cases with positive troponin amongst females than compared to prior trials. Further, Levi *et al.*  
400 discussed a higher immunological response, and subsequent cardiac involvement, observed after the  
401 former BNT1273 vaccination, contrasting to BNT162b2, as a plausible reason for the increased rate of

402 troponin elevations (19, 32). Our study only investigated AZ or the BNT162b vaccine, which may also  
403 account for lower hsTnT levels. Importantly, one crucial limitation of Buerger and colleagues' study  
404 was the missing baseline assessment of hsTnT levels (18). Elevated troponin levels may therefore  
405 have existed prior to vaccination and must, thus, be interpreted with caution.

#### 406 MR-proADM levels after COVID-19 vaccination

407 MR-proADM is a biomarker for endothelial dysfunction and can be elevated for a broad  
408 spectrum of causes. Its release can be related to ongoing infectious processes, which is why MR-  
409 proADM is used as a prognostic marker for sepsis patients, including for cases of severe COVID-19  
410 (20, 21), but also heart failure (24). Especially in the early stages of the pandemic, COVID-19 was  
411 discussed as a disease mainly affecting the vascular system (33). However, a vaccine-associated  
412 endothelial dysfunction has been rarely investigated and, if so, predominantly in the acute post-  
413 vaccination phase (20). Therefore, this study is the first of its kind in which MR-proADM  
414 measurements were performed to assess persistent endothelial damage.

415 At baseline, the median MR-proADM was 0.44nmol/L for the whole study population and  
416 ranged between 0.43 and 0.49nmol/L in the AZ/BNT group and HCW-BNT/BNT sub-cohort; i.e. below  
417 the clinical cut-off of 0.75nmol/L for all HCWs. In the elderly group, a higher median MR-proADM of  
418 0.95nmol/L was observed at V<sub>1</sub>. Accordingly, a significant difference in median MR-proADM levels  
419 was detected when comparing the HCWs and elderly groups; both at enrolment visit V<sub>1</sub> and at V<sub>3</sub>. It  
420 can be assumed that these differences are mostly driven by known age-dependent, naturally higher  
421 values in the senior BNT/BNT sub-group. Furthermore, cardiovascular disease was reported in 70% of  
422 the elderly. From prior literature, we know that MR-proADM remains stably elevated in patients with  
423 pre-existing cardiovascular conditions (34). Focusing on the two younger and healthier HCW cohorts,  
424 no significant differences were detectable at any of the study visit. Moreover, changes in absolute  
425 median MR-proADM levels over time were nearly zero. Overall, 17 participants presented with at  
426 least one MR-proADM value above the clinical cut-off during the course of the study; however, 15 of

427 them had elevated values already at enrolment, indicating that MR-proADM elevation was  
428 independent of vaccination. One case stood out because of a steep MR-proADM increase from visit  
429  $V_2$  to  $V_3$ . However, considering that the participants suffered from an active haematological  
430 malignancy MR-proADM levels may be related to the underlying condition and were interpreted as a  
431 non-vaccine associated effect. The remaining participants showed no relevant kinetic and/or a return  
432 to baseline levels at  $V_3$ . Therefore, our data indicate no evidence of subacute or persistent post-  
433 COVID-19 vaccination endotheliitis, based on MR-proADM measurements. This is in line with the  
434 results a previous study by Terentes-Printzios *et al.* who reported no signs of permanent endothelial  
435 dysfunction after the COVID-19 vaccination by measuring, among other markers, brachial artery-flow  
436 mediated dilatation (20). However, this study reported a transient endothelial impairment in the  
437 immediate 24 hours after vaccination (20); a time point that was not covered in our studies.

438 Association between hsTnT and MR-proADM levels as analysed by Spearman's correlation  
439 were low for both females and males at all visiting times. A prior study by Theuerle *et al.* reported  
440 that MR-proADM may also function as a marker for myocardial damage and strong correlations  
441 between MR-proADM and hsTnT were discussed, without a further sex-dependent analysis. The  
442 researchers emphasised that a combined positive biomarker assay may be associated with a higher  
443 death risk in septic patients (35). While this may well be the case in severely ill patients with  
444 significant cardiovascular damage, our data suggest that hsTnT and MR-proADM correlation is weak  
445 in healthier cohorts with only have mild biomarker elevations.

#### 446 Strengths and Limitations

447 This is a prospective observational cohort study, in which we performed three study visits to  
448 assess persistent myocardial and vascular damage after the COVID-19 vaccination. The comparatively  
449 low sample size limits the statistical power and generalizability of the results. In this context, it must  
450 be acknowledged that the present work was conducted during the ongoing worldwide COVID-19  
451 pandemic; a period characterised by significant political, social as well as research- and healthcare-

452 related turbulence. Thus, the planning and execution of such a study within a constrained timeframe,  
453 involving vaccine-naive individuals was challenging and the number of participants difficult to  
454 regulate. Therefore, a certain validation in larger cohorts may be required in the future. However,  
455 the availability of baseline values and a reference cohort is a major strength over other existing and  
456 possible future studies, since it allows the characterization of vaccine-associated elevation of  
457 biomarkers as compared to baseline and their trajectory over time. At the same time, since time  
458 span between  $V_1$  to  $V_3$  was several weeks, the data cannot definitively prove a causative association  
459 between COVID-19 vaccination and elevated markers of acute cardiovascular damages. Another  
460 limitation is the slightly distinct demographic baseline characteristics of the reference cohort and the  
461 study population, and the lack of available MR-proADM data for the reference cohort. Another  
462 strength of our work is the fact that the study included the 1<sup>st</sup> COVID-19 vaccine dose, and also  
463 compared two different vaccination regimens, which allowed for a broad and longitudinal analysis of  
464 cardiovascular effects of COVID-19 vaccinations. By analysing all troponin changes, regardless of  
465 clinical symptoms and regardless of their absolute level above or below clinical cut-offs provides data  
466 also on potentially mild subclinical adverse effects of COVID-19 vaccines. In addition, to our  
467 knowledge, this is the first study that included an elderly sub-cohort and compared it to a young to  
468 mid-aged cohort. This is significant, since COVID-19 vaccinations are highly effective and most  
469 beneficial with regards to preventing severe diseases and mortality in older risk patients, most of  
470 which present additional with pre-existing conditions.

#### 471 Conclusion and clinical outlook

472 This study shows no relevant hsTnT and MR-proADM increase in temporal association with  
473 COVID-19 vaccination in our cohort. Although the sample size is limited, the cohort is diverse and  
474 covers persons at high risk for both COVID-19 and cardiovascular disease. Thus, the study provides  
475 valuable data that indicate that myocardial cell injury and endothelial dysfunction is not a common  
476 feature of COVID-19 vaccination and was not detectable up to 4 weeks after the 1<sup>st</sup> and 2<sup>nd</sup>  
477 homologous (BNT/BNT) or heterologous (AZ/BNT) COVID-19 vaccination. Hence, based on our data

478 and other available evidence, a general cardiovascular peri-vaccine monitoring is not needed.  
479 However, based on the three individual cases of observed temporal subclinical troponin elevation,  
480 and one HCW case of persistent hsTnT rise, it should be further investigated if males under the age of  
481 40, who suffer from pre-existing cardiovascular conditions or previously documented increase in  
482 hsTnT levels would benefit from active troponin surveillance following COVID-19 vaccination.  
483 However, since the vast majority of the population worldwide has had antigenic experience, often via  
484 multiple doses of vaccines and infections, generalization of our findings to boosters and re-  
485 vaccinations needs to be cautioned. Future research is needed and as of now, all available safety data  
486 underscore the excellent safety and very good risk-benefit ratios of COVID-19 vaccines.

#### 487 **Acknowledgements:**

488 We thank all study participants of the EICOV, COVIMMUNIZE, COVIM, COVIM-Boost and BIC-  
489 1 study. We also thank all members of the EICOV/COVIM Study Group for sample acquisition and  
490 processing: Y. Ahlgrimm, B. Al-Rim, L. Bardtke, K. Behn, N. Bethke, H. Bias, D. Briesemeister, C.  
491 Conrad, V. M. Corman, C. Dang-Heine, S. Dieckmann, D. Frey, J.-A. Gabelich, J. Gerdes, U. Gläser, A.  
492 Hetey, L. Hasler, E. T. Helbig, A. Horn, C. Hülso, S. Jentzsch, C. von Kalle, L. Kegel, A. Krannich, W.  
493 Koch, P. Kopankiewicz, P. Kroneberg, I. Landgraf, L. J. Lippert, M. Lisy, C. Lüttke, P. de Macedo  
494 Gomes, B. Maeß, J. Michel, F. Münn, A. Nitsche, A.-M. Ollech, C. Peiser, A. Pioch, C. Pley, K. Pohl, A.  
495 Richter, M. Rönnefarth, C. Rubisch, L. Ruby, A. Sanchez Rezza, I. Schellenberger, V. Schenkel, J.  
496 Schlesinger, S. Schmidt, S. Schwalgun, G. Schwanitz, T. Schwarz, S. Senaydin, J. Seybold, A.-S.  
497 Sinnigen, A. Solarek, A. Stege, S. Steinbrecher, P. Stubbemann, C. Thibeault and D. Treue.

#### 498 **Sources of funding:**

499 The study was funded by “Forschungsnetzwerk der Universitätsmedizin zu COVID-19”, the  
500 Federal Ministry of Education and Research (BMBF), Zalando SE, the Federal Institute for Drugs and  
501 Medical Devices and intramural funds of Charité - Universitätsmedizin Berlin. The BIC-1 study was

502 performed in collaboration with the Heidelberg university hospital. The funders of the study had no  
503 role in study design, data collection, data analysis, data interpretation, or writing of the report.

504 **Disclosures:**

505 Relating to this specific work, all authors have no conflict of interest to declare. Independent  
506 of this work, M.M. received speakers and consulting fees from Bayer Healthcare, BMS, Boehringer  
507 Ingelheim, Daiichi Sankyo, Astra Zeneca, Sanofi, BRAHMS GmbH and Roche Diagnostics. He received  
508 research funding from German public funding authorities for Health Care Research and Roche  
509 Diagnostics. S.P. receives research funding from Roche Diagnostics.

510 **Data availability statement:**

511 Data can be available upon reasonable request.

512 **References:**

- 513 1. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year  
514 of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis.* 2022;22(9):1293-302.
- 515 2. Rahmani K, Shavaleh R, Forouhi M, Disfani HF, Kamandi M, Oskooi RK, et al. The effectiveness  
516 of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A  
517 systematic review and meta-analysis. *Front Public Health.* 2022;10:873596.
- 518 3. University of Oxford. Coronavirus (COVID-19) vaccinations. 2023. Available from:  
519 <https://ourworldindata.org/covid-vaccinations>. Last accessed: 04 August 2023.
- 520 4. Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-  
521 19 Vaccination. 2023. Available from: [https://www.cdc.gov/coronavirus/2019-  
522 ncov/vaccines/safety/adverse-events.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html). Last accessed: 04 August 2023.
- 523 5. European Medicines Agency. Safety of COVID-19 vaccines. 2023. Available from:  
524 [https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-  
525 disease-covid-19/covid-19-medicines/safety-covid-19-  
526 vaccines#:~:text=Reports%20of%20suspected%20side%20effects,-](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines#:~:text=Reports%20of%20suspected%20side%20effects,-)

- 527 [Information%20on%20reports&text=Almost%20768%20million%20vaccine%20doses,every%20100%](#)  
528 [20administered%20vaccine%20doses](#). Last accessed: 04 August 2023.
- 529 6. ICMRA. ICMRA statement on the safety of COVID-19 vaccines. Available from:  
530 [https://icmra.info/drupal/strategicinitiatives/vaccines/safety\\_statement](https://icmra.info/drupal/strategicinitiatives/vaccines/safety_statement). Last accessed: 07 February  
531 2024.
- 532 7. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19  
533 Vaccination in a Large Health Care Organization. *N Engl J Med*. 2021;385(23):2132-9.
- 534 8. Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, et al. Risk of myocarditis and  
535 pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.  
536 *Lancet*. 2022;399(10342):2191-9.
- 537 9. Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence,  
538 biomarkers, mechanisms and potential therapies. *Acta Pharmacol Sin*. 2023;44(4):695-709.
- 539 10. Yasmin F, Najeeb H, Naeem U, Moeed A, Atif AR, Asghar MS, et al. Adverse events following  
540 COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and  
541 thrombocytopenia. *Immun Inflamm Dis*. 2023;11(3):e807.
- 542 11. Paknahad MH, Yancheshmeh FB, Soleimani A. Cardiovascular complications of COVID-19  
543 vaccines: A review of case-report and case-series studies. *Heart Lung*. 2023;59:173-80.
- 544 12. Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, Hartling L. Incidence, risk  
545 factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following  
546 covid-19 vaccination: living evidence syntheses and review. *BMJ*. 2022;378:e069445.
- 547 13. Husby A, Hansen JV, Fosbol E, Thiesson EM, Madsen M, Thomsen RW, et al. SARS-CoV-2  
548 vaccination and myocarditis or myopericarditis: population based cohort study. *BMJ*.  
549 2021;375:e068665.
- 550 14. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis Cases Reported  
551 After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. *JAMA*.  
552 2022;327(4):331-40.

- 553 15. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis  
554 Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA*  
555 *Cardiol.* 2021;6(10):1202-6.
- 556 16. Mansanguan S, Charunwatthana P, Piyaphanee W, Dechkhajorn W, Poolcharoen A,  
557 Mansanguan C. Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in  
558 Adolescents. *Trop Med Infect Dis.* 2022;7(8).
- 559 17. Levi N, Moravsky G, Weitsman T, Amsalem I, Bar-Sheshet Itach S, Algur N, et al. A prospective  
560 study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy  
561 persons. *Eur J Heart Fail.* 2023;25(2):313-8.
- 562 18. Buergin N, Lopez-Ayala P, Hirsiger JR, Mueller P, Median D, Glarner N, et al. Sex-specific  
563 differences in myocardial injury incidence after COVID-19 mRNA-1273 booster vaccination. *Eur J*  
564 *Heart Fail.* 2023.
- 565 19. Levi N, Hasin T. Myocardial injury related to SARS-CoV-2 mRNA vaccination: The plot  
566 thickens. *Eur J Heart Fail.* 2023;25(10):1882-3.
- 567 20. Terentes-Printzios D, Gardikioti V, Solomou E, Emmanouil E, Gourgouli I, Xydis P, et al. The  
568 effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness. *Hypertens*  
569 *Res.* 2022;45(5):846-55.
- 570 21. Gregoriano C, Koch D, Kutz A, Haubitz S, Conen A, Bernasconi L, et al. The vasoactive peptide  
571 MR-pro-adrenomedullin in COVID-19 patients: an observational study. *Clin Chem Lab Med.*  
572 2021;59(5):995-1004.
- 573 22. Smith C. The structural vulnerability of healthcare workers during COVID-19: Observations on  
574 the social context of risk and the equitable distribution of resources. *Soc Sci Med.* 2020;258:113119.
- 575 23. Liu E, Dean CA, Elder KT. Editorial: The impact of COVID-19 on vulnerable populations. *Front*  
576 *Public Health.* 2023;11:1267723.



- 577 24. Mockel M, Koehler K, Anker SD, Vollert J, Moeller V, Koehler M, et al. Biomarker guidance  
578 allows a more personalized allocation of patients for remote patient management in heart failure:  
579 results from the TIM-HF2 trial. *Eur J Heart Fail.* 2019;21(11):1445-58.
- 580 25. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC  
581 Guidelines for the management of acute myocardial infarction in patients presenting with ST-  
582 segment elevation: The Task Force for the management of acute myocardial infarction in patients  
583 presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J.*  
584 2018;39(2):119-77.
- 585 26. Barbier CE, Themudo R, Bjerner T, Johansson L, Lindahl B, Venge P, et al. Cardiac troponin I  
586 associated with the development of unrecognized myocardial infarctions detected with MRI. *Clin*  
587 *Chem.* 2014;60(10):1327-35.
- 588 27. Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al. Prevalence and Impact  
589 of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. *J Am Coll Cardiol.*  
590 2020;76(5):533-46.
- 591 28. Orlev A, Klempfner R, Rott D. Serum Cardiac Troponin T Levels in Asymptomatic Elderly  
592 Nursing Home Residents. *Am J Med.* 2018;131(7):842-5.
- 593 29. Sedighi SM, Fulop T, Mohammadpour A, Nguyen M, Prud'Homme P, Khalil A. Elevated  
594 Cardiac Troponin Levels in Geriatric Patients Without ACS: Role of Comorbidities. *CJC Open.*  
595 2021;3(3):248-55.
- 596 30. Herman DS, Kavsak PA, Greene DN. Variability and Error in Cardiac Troponin Testing: An  
597 ACLPS Critical Review. *Am J Clin Pathol.* 2017;148(4):281-95.
- 598 31. Lan NSR, Bell DA. Revisiting the Biological Variability of Cardiac Troponin: Implications for  
599 Clinical Practice. *Clin Biochem Rev.* 2019;40(4):201-16.
- 600 32. Abraham N, Spruin S, Rossi T, Fireman B, Zafack J, Blaser C, et al. Myocarditis and/or  
601 pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of  
602 BNT162b2 and mRNA-1273 vaccines. *Vaccine.* 2022;40(32):4663-71.

603 33. Siddiqi HK, Libby P, Ridker PM. COVID-19 - A vascular disease. Trends Cardiovasc Med.  
604 2021;31(1):1-5.


605 34. Potocki M, Ziller R, Mueller C. Mid-regional pro-adrenomedullin in acute heart failure: a  
606 better biomarker or just another biomarker? Curr Heart Fail Rep. 2012;9(3):244-51.

607 35. Theuerle J, Farouque O, Vasanthakumar S, Patel SK, Burrell LM, Clark DJ, Al-Fiadh AH. Plasma  
608 endothelin-1 and adrenomedullin are associated with coronary artery function and cardiovascular  
609 outcomes in humans. Int J Cardiol. 2019;291:168-72.

610

611 **Figures and figure legends:**

612 **Structured graphical abstract:**



613


614

615 Summary of the vaccination scheme and visiting points in the study population (of HCWs and seniors  
616 > 70 years) between the 12<sup>th</sup> of January and the 30<sup>th</sup> of November 2021. The results showed no  
617 overall subtle, chronic myocardial or vascular involvement in our COVID-19 vaccinated cohorts.

618 **Abbreviations:** AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2  
 619 messenger ribonucleic acid vaccine from BioNTech, EDTA Ethylenediaminetetraacetic acid, HCWs  
 620 health care workers, hsTnT high-sensitive troponin T, mid-regional pro-adrenomedullin, V<sub>1</sub>-V<sub>3</sub> visiting  
 621 times 1-3, w week(s).

622

623 **Figure 1.**



624

625




626 Study population diagram. Recruitment of vulnerable study population with cohort 1 including health  
 627 care workers and cohort 2 including elderly general practitioner patients. Vaccinations with either a  
 628 heterogenous combination of AZ/BNT or a homologous scheme of BNT/BNT were applied and three  
 629 main visits V<sub>1</sub> to V<sub>3</sub> were performed.

630 \* One hospital employee of the BNT/BNT cohort did not participate in the enrolment visit V<sub>1</sub> but  
 631 received both BNT vaccinations regularly and took part in the visits V<sub>2</sub>, V<sub>3</sub> and is, therefore, included  
 632 in this study.

633 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2  
634 messenger ribonucleic acid vaccine from BioNTech, V<sub>1</sub>-V<sub>5</sub> visiting times 1-5, w week(s).

635

636 **Figure 2.**




637

638 **A.** HsTnT values at the three main visiting points for participants of the AZ/BNT and BNT/BNT group  
639 (HCWs and elderly), separated by sex. The red dashed line indicates the 14 ng/L threshold. **B.** Box  
640 plots of the change of hsTnT values between each visiting time ( $V_1$ - $V_2$ ,  $V_1$ - $V_3$ ,  $V_1$ - $V_3$ ), separated by  
641 AZ/BNT and BNT/BNT group. **C.** Box plots of the change of hsTnT values between each visiting time  
642 ( $V_1$ - $V_2$ ,  $V_1$ - $V_3$ ,  $V_1$ - $V_3$ ), separated by AZ/BNT, HCW BNT/BNT and senior BNT/BNT group.

643 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2  
644 messenger ribonucleic acid vaccine from BioNTech, hsTnT high-sensitive troponin T,  $V_1$ - $V_3$  visiting  
645 times 1-3.

646

647 **Figure 3.**



648

649 Box plots of hsTnT levels of the reference group (orange) compared to the AZ/BNT group (blue) and  
650 the BNT/BNT group (HCWs: green; elderly: red) at  $V_1$  to  $V_3$ . The red dashed line indicates the 14 ng/L  
651 threshold.

652 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2  
653 messenger ribonucleic acid vaccine from BioNTech, hsTnT high-sensitive troponin T, V<sub>1</sub>-V<sub>3</sub> visiting  
654 times 1-3.

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669




670

671

672

673 **Figure 4.**

674



675

676 **A.** MR-proADM values at the three main visiting points for participants of the AZ/BNT and BNT/BNT  
 677 group (including HCWs and elderly), separated by sex. The red dashed line indicates the 0.75 nmol/L  
 678 threshold. **B.** Box plots of the change of MR-proADM values between each visiting time ( $V_1$ - $V_2$ ,  $V_1$ - $V_3$ ,  
 679  $V_1$ - $V_3$ ).

680 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2  
 681 messenger ribonucleic acid vaccine from BioNTech, MR-proADM mid-regional pro-adrenomedullin,  
 682  $V_1$ - $V_3$  visiting times 1-3.

683

684 **Tables and table legends:**

685 **Table 1.** Baseline characteristics of the study cohort and reference group.

Characteristics	COVIM study					BIC-1 study
	All participants	AZ/BNT	BNT/BNT			Reference group
			In total	HCWs	elderly	
<b>Numbers (n)</b>	<b>162</b>	<b>74</b>	<b>88</b>	<b>68</b>	<b>20</b>	<b>300</b>
<b>Patient characteristics</b>						
Age, years <sup>#</sup>	35.6 (30.0-54.1)	33.2 (29.7-45.3)	37.6 (31.1-59.6)	34.2 (29.7-44.0)	83.7 (80.7-87.0)	39.0 (33.0-46.0)
Sex, female	90 (56%)	41 (55%)	49 (56%)	34 (50%)	15 (75%)	150 (50%)
BMI, kg/m <sup>2</sup> # <sup>1</sup>	23.9 (21.5-25.8)	23.9 (21.7-25.7)	23.8 (21.3-26.1)	24.1 (21.6-26.1)	23.2 (21.5-26.0)	24.9 (22.4-27.7)
Former smokers	6/148 (4.0%)	2/72 (2.7%)	4/76 (5.2%)	4/56 (7.14%)	0/20 (0%)	61/300 (20.3%)
Current smokers	10/148 (6.7%)	4/72 (5.5%)	6/76 (7.8%)	5/56 (8.9%)	1/20 (5%)	105/300 (35.0%)
<b>Comorbidities*</b>						
<b>Cardiovascular diseases</b>	21/162 (13.0%)	4/74 (5.4%)	17/88 (19.3%)	3/68 (4.4%)	14/20 (70%)	n. a.
Hypertonus	20/162 (12.3%)	4/74 (5.4%)	16/88 (18.2%)	3/68 (4.4%)	13/20 (65%)	



Heart insufficiency	4/162 (2.5%)	0	4/88 (4.5%)	0	4/20 (20%)	
Heart rhythm disorder	3/162 (1.9%)	0	3/88 (3.4%)	0	3/20 (15%)	
Myocardial infarction, Angina pectoris, peripheral artery disease, carotid stenosis	3/162 (1.95%)	0	3/88 (3.4%)	0	3/20 (15%)	
<b>Chronic lung diseases</b>	10/162 (6.2%)	4/74 (5.4%)	6/88 (6.8%)	4/68 (5.9%)	2/20 (10%)	
Asthma	6/162 (3.7%)	3/74 (4.1%)	3/88 (3.4%)	3/68 (4.4%)	0	
Chronic Bronchitis	1/162 (0.6%)	0	1/88 (1.1%)	1/68 (1.5%)	0	
COPD	3/162 (1.9%)	1/74 (1.4%)	2/88 (2.3%)	0	2/20 (10%)	
<b>Kidney diseases</b>	7/162 (4.3%)	1/74 (1.4%)	6/88 (6.8)	0	6/20 (30%)	
<b>Cancer</b>	7/162 (4.3%)	3/74 (4.1%)	4/88 (4.5%)	1/68 (1.5%)	3/20 (15%)	
<b>Pre-medication*</b>						
Immunosuppression	9/162 (5.6%)	2/74 (2.7%)	7/88 (8.0%)	3/68 (4.4%)	4/20 (20%)	n. a.
Corticosteroids	4/162 (2.5%)	1/74 (1.4%)	3/88 (3.4%)	0	3/20 (15%)	
Antihypertensive drugs	14/162 (8.6%)	2/74 (2.7%)	12/88 (13.6%)	1/68 (1.5%)	11/20 (55%)	
Anticoagulants	3/162 (1.9%)	0	3/88 (3.4%)	0	3/20 (15%)	
Antiplatelet drugs	4/162 (2.5%)	0	4/88 (4.5%)	0	4/20 (20%)	
<b>Baseline biomarker values</b>						
hsTnT (V <sub>1</sub> , V <sub>R-1</sub> ), ng/dl <sup>#</sup>	5 (4-7)	4 (4-6)	5 (4-8)	5 (4-6)	18 (11-29)	3.6 (3.0-4.9)
MR-proADM (V <sub>1</sub> ), nmol/L <sup>#</sup>	0.44 (0.40-0.55)	0.43 (0.39-0.47)	0.49 (0.42-0.63)	0.44 (0.40-0.54)	0.95 (0.65-1.01)	n. a.

686

687 \*: more than one choice possible. #: median with interquartile range (IQR). N.a.: not applicable. <sup>1</sup> BMI

688 values were available 147 participants in total with 73 AZ/BNT individuals and 74 BNT/BNT people.

689 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BMI Body-Mass-  
 690 Index, BNT BNT162b2 messenger ribonucleic acid vaccine from BioNTech, COPD Chronic Obstructive  
 691 Pulmonary Disease, hsTnT high-sensitive troponin T, MR-proADM mid-regional pro-adrenomedullin.

692

693 **Table 2.** Mixed-effects regression models for the course of hsTnT and MR-proADM in HCWs with  
 694 visits as repeated measurements and random effects for the intercept. All other variables are treated  
 695 as fixed effects.

Parameter	hsTnT		MRproADM	
	$\beta$ (95% CI)	p	$\beta$ (95% CI)	p
intercept	1.922 (0.66;3.184)	0.003	0.289 (0.238;0.341)	<0.001
BNT/BNT vaccination (ref. AZ/BNT)	0.362 (-0.287;1.011)	0.272	0.013 (-0.014;0.04)	0.341
age (per 10 years)	0.599 (0.309;0.890)	<0.001	0.045 (0.033;0.057)	<0.001
male sex	1.162 (0.427;1.896)	0.002	-0.011 (-0.038;0.016)	0.407
V <sub>2</sub> (ref. V <sub>1</sub> )	0.41 (0.124;0.696)	0.005	0.007 (-0.003;0.018)	0.178
V <sub>3</sub> (ref. V <sub>1</sub> )	0.135 (-0.152;0.421)	0.356	0.009 (-0.002;0.021)	0.120

696

697 Abbreviations: BNT BNT162b2 messenger ribonucleic acid vaccine from BioNTech, CI confidence  
 698 interval, hsTnT high-sensitive troponin T, MR-proADM mid-regional pro-adrenomedullin, ref.  
 699 reference to, V<sub>1</sub>-V<sub>3</sub> visiting times 1-3, 95% CI 95% confidence interval.

700


701

702

703

704 **Appendices:**

705 **Supplementary figure 1.**



706

707 Study population diagram of the follow-up study COVIM-Boost. A 3<sup>rd</sup> (and optionally 4<sup>th</sup>) vaccination  
708 was done and visit data was collected at V<sub>4</sub> and V<sub>5</sub>.

709 Abbreviations: BNT BNT162b2 messenger ribonucleic acid vaccine from BioNTech, MOD messenger  
710 ribonucleic acid -1273 vaccine from Moderna, V<sub>1</sub>-V<sub>5</sub> visiting times 1-5, w week(s).

711

712

713


714

715


716

717 **Supplementary figure 2. A.** HsTnT values at all six visiting points (including the follow ups) for  
718 participants of the AZ/BNT and BNT/BNT HCW group (HCWs and elderly), separated by sex.

**A**



**B**




719

720 The red dashed line indicates the 14 ng/L threshold. **B.** Box plots of the change of hsTnT values  
721 between each visiting time ( $V_1-V_2$ ,  $V_1-V_3$ ,  $V_1-V_3$ ).

722 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2  
723 messenger ribonucleic acid vaccine from BioNTech, HCW health care workers, hsTnT high-sensitive  
724 troponin T.

725 **Supplementary figure 3.** MR-proADM values at the five visiting points ( $V_1$ - $V_5$ ) for participants of the  
726 AZ/BNT and BNT/BNT group (including HCWs and elderly), separated by sex.



727

728 The red dashed line indicates the 0.75 nmol/L threshold.

729 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2  
730 messenger ribonucleic acid vaccine from BioNTech, MR-proADM mid-regional pro-adrenomedullin,  
731  $V_1$ - $V_5$  visiting times 1-5.

732

733

734

735


736

737

738

739

740 **Supplementary figure 4.** The correlation scatter plots are presented separately for sex with  
741 Spearman correlation coefficients. **A)** Correlation between hsTnT and MR-proADM values at all 3  
742 visits. **B)** Correlation between age and MR-proADM levels at V<sub>1</sub>. **C)** Correlation between age and  
743 hsTnT levels at V<sub>1</sub>.



744

745 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2  
746 messenger ribonucleic acid vaccine from BioNTech, hsTnT high-sensitive troponin T, MR-proADM  
747 mid-regional pro-adrenomedullin.

748

749

750

751

752 **Supplementary table 1.** Mixed-effects regression models for propensity score-matched groups.

Parameter	hsTnT		MRproADM	
	$\beta$ (95% CI)	p	$\beta$ (95% CI)	p
intercept	2.161 (0.954;3.367)	<0.001	0.320 (0.270;0.370)	<0.001
BNT/BNT vaccination (ref. AZ/BNT)	0.335 (-0.026;0.697)	0.069	0.014 (-0.001;0.029)	0.067
age (per 10 years)	0.555 (0.276;0.833)	<0.001	0.037 (0.025;0.048)	<0.001
male sex	1.391 (0.905;1.878)	<0.001	-0.012 (-0.032;0.008)	0.229
V <sub>2</sub> (ref. V <sub>1</sub> )	0.440 (-0.001;0.881)	0.050	0.007 (-0.010;0.025)	0.391
V <sub>3</sub> (ref. V <sub>1</sub> )	0.139 (-0.301;0.580)	0.534	0.007 (-0.011;0.025)	0.453

753

754 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2

755 messenger ribonucleic acid vaccine from BioNTech, hsTnT high-sensitive troponin T, MR-proADM

756 mid-regional pro-adrenomedullin, ref. reference, V<sub>1</sub>-V<sub>3</sub> visiting times 1-3, 95% CI 95% confidence

757 interval.